Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.39 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.39 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.39 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1824001 | 1.00 | MAPT (0.47) | MAPTALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL3312582 | 1.00 | MAPT (0.47) | MAPTALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL29097448 | 1.00 | MAPT (0.47) | MAPTALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL1824002 | 1.00 | MAPT (0.47) | MAPTALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL9137960 | 0.86 | MAPT (0.55) | MAPTALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL11073044 | 0.86 | MAPT (0.55) | MAPTALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL8512702 | 0.86 | MAPT (0.55) | MAPTALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL8512700 | 0.86 | MAPT (0.55) | MAPTALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL4962623 | 0.85 | MAPT (0.52) | MAPTALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL652994 | 0.85 | MAPT (0.52) | MAPTALDH1A1POLBKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470784-B2 | Methods for synthesizing 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-9H-purin-6-amine | SOUTHERN RESEARCH INSTITUTE (US) | 2008-12-30 | — | — | US | claimed |
| EP-0428109-A2 | Deoxyfluoronucleoside process | Bristol-Myers Squibb Company (US) | 1991-05-22 | — | — | EP | claimed |
| JP-3170496-A | — | — | None | — | — | JP | disclosed |
| CN-114288313-B | Application of pyrimidine nucleoside medicine in preparing medicine for preventing or treating coronavirus infectious diseases | 常晓宇 | 2023-07-04 | — | — | CN | disclosed |
| CN-114288313-A | Application of pyrimidine nucleoside medicament in preparing medicament for preventing or treating coronavirus infectious diseases | 常晓宇 | 2022-04-08 | — | — | CN | disclosed |
| US-20220033432-A1 | ANTI-HEPATITIS B VIRUS AGENT | DAIKIN INDUSTRIES, LTD. (JP) | 2022-02-03 | — | — | US | disclosed |
| EP-3939655-A1 | ANTI-HEPATITIS B VIRUS AGENT | DAIKIN INDUSTRIES, LTD. (JP) | 2022-01-19 | — | — | EP | disclosed |
| US-20220008450-A1 | ANTI-HEPATITIS B VIRUS AGENT | DAIKIN INDUSTRIES, LTD. (JP) | 2022-01-13 | — | — | US | disclosed |
| EP-3862004-A1 | ANTI-HEPATITIS B VIRUS AGENT | DAIKIN INDUSTRIES, LTD. (JP) | 2021-08-11 | — | — | EP | disclosed |
| EP-1019425-A1 | MODIFIED BENZIMIDAZOLE NUCLEOSIDES AS ANTIVIRAL AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2000-07-19 | — | — | EP | disclosed |
| US-5840743-A | TREATING HERPES VIRUS, CYTOMEGALO VIRUS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1998-11-24 | — | — | US | disclosed |
| US-5744597-A | Stereoselective anion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides | ELI LILLY AND COMPANY (US) | 1998-04-28 | — | — | US | disclosed |
| WO-1997027204-A1 | MODIFIED BENZIMIDAZOLE NUCLEOSIDES AS ANTIVIRAL AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1997-07-31 | — | — | WO | disclosed |
| JP-H03170496-A | PROCESS FOR PREPARATION OF DEOXYFLUORONUCLEOSIDE | BRISTOL MYERS SQUIBB CO | 1991-07-24 | — | — | JP | disclosed |
| EP-0428109-A2 | Deoxyfluoronucleoside process | Bristol-Myers Squibb Company (US) | 1991-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033432-A1 | ANTI-HEPATITIS B VIRUS AGENT | SLC10A1, HAVCR2, FABP1 | MAPT 3916/4885ALDH1A1 1190/4885POLB 10/4885 |
| US-20220008450-A1 | ANTI-HEPATITIS B VIRUS AGENT | HAVCR2, ADAR, ADA | MAPT 3374/4885ALDH1A1 937/4885POLB 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.